Role of Iron in Neurodegenerative Diseases

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2016 Jan 23

PMID 26794939

Citations 41

Authors

Kai Li

Heinz Reichmann

Affiliations

Soon will be listed here.

Abstract

Currently, we still lack effective measures to modify disease progression in neurodegenerative diseases. Iron-containing proteins play an essential role in many fundamental biological processes in the central nervous system. In addition, iron is a redox-active ion and can induce oxidative stress in the cell. Although the causes and pathology hallmarks of different neurodegenerative diseases vary, iron dyshomeostasis, oxidative stress and mitochondrial injury constitute a common pathway to cell death in several neurodegenerative diseases. MRI is capable of depicting iron content in the brain, and serves as a potential biomarker for early and differential diagnosis, tracking disease progression and evaluating the effectiveness of neuroprotective therapy. Iron chelators have shown their efficacy against neurodegeneration in a series of animal models, and been applied in several clinical trials. In this review, we summarize recent developments on iron dyshomeostasis in Parkinson's disease, Alzheimer's disease, Friedreich ataxia, and Huntington's disease.

Citing Articles

Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases.

Chen L, Shen Q, Liu Y, Zhang Y, Sun L, Ma X Signal Transduct Target Ther. 2025; 10(1):31.

PMID: 39894843 PMC: 11788444. DOI: 10.1038/s41392-024-02071-0.

The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications.

Kim S, Jung U, Kim S J Clin Med. 2025; 14(2).

PMID: 39860392 PMC: 11765772. DOI: 10.3390/jcm14020386.

PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.

Gujral J, Gandhi O, Singh S, Ahmed M, Ayubcha C, Werner T Am J Nucl Med Mol Imaging. 2025; 14(6):371-390.

PMID: 39840378 PMC: 11744359. DOI: 10.62347/AICM8774.

Fatigue Assessment in Patients with Hereditary Hemochromatosis: First Use of the Popular Diagnostic Tools.

Swiatczak M, Raczak A, Swiatczak A, Mlodzinski K, Sikorska K, Jazwinska A J Clin Med. 2024; 13(18).

PMID: 39337031 PMC: 11432497. DOI: 10.3390/jcm13185544.

Iron-Status Indicators and HFE Gene Polymorphisms in Individuals with Amyotrophic Lateral Sclerosis: An Umbrella Review of Meta-analyses and Systematic Reviews.

Khoshdooz S, Abbasi H, Abbasi M Biol Trace Elem Res. 2024; .

PMID: 39317854 DOI: 10.1007/s12011-024-04391-2.

References

Chen J, Marks E, Lai B, Zhang Z, Duce J, Lam L . Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS One. 2013; 8(10):e77023. PMC: 3795666. DOI: 10.1371/journal.pone.0077023. View

Moos T, Morgan E . The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain. J Neurochem. 2003; 88(1):233-45. DOI: 10.1046/j.1471-4159.2003.02142.x. View

Skjorringe T, Burkhart A, Johnsen K, Moos T . Divalent metal transporter 1 (DMT1) in the brain: implications for a role in iron transport at the blood-brain barrier, and neuronal and glial pathology. Front Mol Neurosci. 2015; 8:19. PMC: 4458610. DOI: 10.3389/fnmol.2015.00019. View

Berg D . Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. J Neural Transm (Vienna). 2010; 118(3):453-61. DOI: 10.1007/s00702-010-0469-5. View

Guerreiro C, Silva B, Crespo A, Marques L, Costa S, Timoteo A . Decrease in APP and CP mRNA expression supports impairment of iron export in Alzheimer's disease patients. Biochim Biophys Acta. 2015; 1852(10 Pt A):2116-22. DOI: 10.1016/j.bbadis.2015.07.017. View

Grossi C, Francese S, Casini A, Rosi M, Luccarini I, Fiorentini A . Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2009; 17(2):423-40. DOI: 10.3233/JAD-2009-1063. View

Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H . Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord. 2007; 22(6):839-42. DOI: 10.1002/mds.21413. View

Koeppen A, Ramirez R, Yu D, Collins S, Qian J, Parsons P . Friedreich's ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus. Cerebellum. 2012; 11(4):845-60. PMC: 3497958. DOI: 10.1007/s12311-012-0383-5. View

Carroll C, Zeissler M, Chadborn N, Gibson K, Williams G, Zajicek J . Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease. Neurochem Int. 2011; 59(1):73-80. DOI: 10.1016/j.neuint.2011.05.006. View

10.

Crichton R, Dexter D, Ward R . Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm (Vienna). 2010; 118(3):301-14. DOI: 10.1007/s00702-010-0470-z. View

11.

Devi L, Raghavendran V, Prabhu B, Avadhani N, Anandatheerthavarada H . Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008; 283(14):9089-100. PMC: 2431021. DOI: 10.1074/jbc.M710012200. View

12.

Hansen T, Nielsen H, Bernth N, Moos T . Expression of ferritin protein and subunit mRNAs in normal and iron deficient rat brain. Brain Res Mol Brain Res. 1999; 65(2):186-97. DOI: 10.1016/s0169-328x(99)00011-x. View

13.

Koeppen A, Kuntzsch E, Bjork S, Ramirez R, Mazurkiewicz J, Feustel P . Friedreich ataxia: metal dysmetabolism in dorsal root ganglia. Acta Neuropathol Commun. 2013; 1:26. PMC: 3893523. DOI: 10.1186/2051-5960-1-26. View

14.

Petrucelli L, Hardy J, Lee J, Farer M, Wolozin B . The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci. 2000; 20(16):6048-54. PMC: 6772599. View

15.

Wan L, Nie G, Zhang J, Luo Y, Zhang P, Zhang Z . β-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med. 2010; 50(1):122-9. DOI: 10.1016/j.freeradbiomed.2010.10.707. View

16.

Geppert M, Hohnholt M, Nurnberger S, Dringen R . Ferritin up-regulation and transient ROS production in cultured brain astrocytes after loading with iron oxide nanoparticles. Acta Biomater. 2012; 8(10):3832-9. DOI: 10.1016/j.actbio.2012.06.029. View

17.

Silvestri L, Camaschella C . A potential pathogenetic role of iron in Alzheimer's disease. J Cell Mol Med. 2008; 12(5A):1548-50. PMC: 3918070. DOI: 10.1111/j.1582-4934.2008.00356.x. View

18.

Lane D, Merlot A, Huang M, Bae D, Jansson P, Sahni S . Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease. Biochim Biophys Acta. 2015; 1853(5):1130-44. DOI: 10.1016/j.bbamcr.2015.01.021. View

19.

Kwon D, Kim J, Oh S, Jeong H, Park S, Oh E . Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol. 2012; 71(2):267-77. DOI: 10.1002/ana.22592. View

20.

Devos D, Moreau C, Devedjian J, Kluza J, Petrault M, Laloux C . Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal. 2013; 21(2):195-210. PMC: 4060813. DOI: 10.1089/ars.2013.5593. View